David A. Bilson

Specialty / focus. David A. Bilson is a Delaware IP litigation associate whose docket is dominated by Hatch-Waxman/ANDA pharmaceutical patent litigation in the District of Delaware, typically as local counsel for generic drug companies. The tracked cases are all in the Novartis v. Handa GILENYA® (fingolimod) litigation (D. Del. No. 1:21-cv-00645 and related actions), but court dockets show the same pattern across Pharmacyclics v. Cipla, Biogen v. Glenmark, Ferring v. Lupin, Gilead v. Lupin, Pfizer v. Apotex, Astellas v. Zydus, Celgene v. InnoPharma, and the In re Auryxia MDL. He also handles non-pharma patent work (e.g., PayRange v. CSC ServiceWorks, involving mobile-payment/software patents, and ITT v. Tenneco, where he appeared for the plaintiff).

Side preference and firm context. Bilson works almost entirely on the defense side: all three tracked appearances are for defendants (two as local counsel, one as defense counsel), matching his broader docket of generic-pharma and operating-company defendants. He is an associate at Phillips, McLaughlin & Hall, P.A., a six-attorney Wilmington litigation boutique; earlier docket entries (circa 2016–2018) list the firm under its prior name, Phillips, Goldman, McLaughlin & Hall. Public records show no prior-firm history; his career appears to have been spent at this firm.

Notable cases / PTAB. The most prominent tracked matter is Novartis v. Handa Neuroscience (GILENYA), in which Bilson and the firm represented the Handa entities; Judge Stark denied Handa's motion to dismiss/transfer in March 2022, and the case terminated in October 2022. In PayRange v. CSC ServiceWorks, he appeared for defendant CSC in connection with a stay pending inter partes review of the asserted patents. There is no evidence he appears regularly as counsel of record in IPR/PGR proceedings before the PTAB; his PTAB exposure appears limited to stay-pending-IPR practice in district court.

Bar / education. Bilson received his J.D., magna cum laude, from Temple University School of Law (2001) and a B.A., summa cum laude, from Neumann College (1998); he is admitted in New Jersey and Pennsylvania (2001) and Delaware (2007) (Martindale-Hubbell).